Cargando…
437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patient...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644557/ http://dx.doi.org/10.1093/ofid/ofab466.636 |
_version_ | 1784610113707835392 |
---|---|
author | Green, Amanda M Souquette, Aisha Agrawal, Mona Wolf, Joshua Wolf, Joshua Gaur, Aditya Allison, Kim J Estepp, Jeremie Allen, Emma Thomas, Paul Smallwood, Heather |
author_facet | Green, Amanda M Souquette, Aisha Agrawal, Mona Wolf, Joshua Wolf, Joshua Gaur, Aditya Allison, Kim J Estepp, Jeremie Allen, Emma Thomas, Paul Smallwood, Heather |
author_sort | Green, Amanda M |
collection | PubMed |
description | BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patients with severe COVID-19 rarely display CSS cytokine phenotypes, and may have more limited inflammatory responses instead. METHODS: Prospective cohorts, aged 0-90 years of age who tested positive by polymerase chain reaction (PCR) for SARS-CoV-2 were enrolled from inpatient hospitals and outpatient testing centers in Memphis, TN from May 2020-January 2021. Longitudinal blood samples were obtained including acute, sub-acute and convalescent timepoints. Severity scores of asymptomatic, mild, moderate, and severe COVID-19 were assigned at time of convalescent assessment. Plasma was analyzed with a quantitative human magnetic 38-plex cytokine assay. RESULTS: : 169 participants were enrolled, including 8 asymptomatic, 117 mild, 22 moderate and 17 severe cases, and 5 children with post-COVID-19 multisystem inflammatory syndrome in children (MIS-C). All moderate and severe patients were hospitalized and received treatment (39%). Clear distinctions were seen between asymptomatic-mild cases and moderate-severe cases at acute timepoints and during disease progression for GCSF, IL-8, IL-10, IL-15, IL-1Ra, IP-10, MIP-1a, MIP-1β, and TGFα. There was a significant difference between participants who did and did not require hospitalization for acute timepoint levels of IL-10, IL-15, MIP-1 β and TGFα (p< 0.01). Only 4 participants with active COVID-19 were found to meet criteria for CSS (2%), only 3 of which were severe. MIS-C participants showed nearly universally elevated cytokine levels compared to those with active COVID-19. Temporal and severity associations of IL-10 and IP-10 [Image: see text] Figure 1. Temporal and severity associations of IL-10 and IP-10 Examples of differentiating cytokine profiles by severity and time. Among SARS-CoV-2 PCR positive participants, IL-10 and IP-10 displayed increased levels in their acute plasma samples as clinical severity increased [A,C]. IL-10 and IP-10 also showed distinct time-dependent responses (ln(Cytokine level (pg/mL)) that differentiated the more severe from the less severe groups [B,D]. CONCLUSION: Moderate and severe acute COVID-19 has a distinct cytokine profile from asymptomatic and mild cases, as detected from acute, subacute and convalescent plasma. DISCLOSURES: Joshua Wolf, MBBS, PhD, FRACP, Karius Inc. (Research Grant or Support) Joshua Wolf, MBBS, PhD, FRACP, Nothing to disclose Paul Thomas, PhD, Cytoagents (Consultant)Immunoscape (Consultant) |
format | Online Article Text |
id | pubmed-8644557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86445572021-12-06 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups Green, Amanda M Souquette, Aisha Agrawal, Mona Wolf, Joshua Wolf, Joshua Gaur, Aditya Allison, Kim J Estepp, Jeremie Allen, Emma Thomas, Paul Smallwood, Heather Open Forum Infect Dis Poster Abstracts BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infection with widely varying clinical severity. Severe COVID-19 was initially proposed to be secondary to cytokine storm syndrome (CSS). However, studies since showed that patients with severe COVID-19 rarely display CSS cytokine phenotypes, and may have more limited inflammatory responses instead. METHODS: Prospective cohorts, aged 0-90 years of age who tested positive by polymerase chain reaction (PCR) for SARS-CoV-2 were enrolled from inpatient hospitals and outpatient testing centers in Memphis, TN from May 2020-January 2021. Longitudinal blood samples were obtained including acute, sub-acute and convalescent timepoints. Severity scores of asymptomatic, mild, moderate, and severe COVID-19 were assigned at time of convalescent assessment. Plasma was analyzed with a quantitative human magnetic 38-plex cytokine assay. RESULTS: : 169 participants were enrolled, including 8 asymptomatic, 117 mild, 22 moderate and 17 severe cases, and 5 children with post-COVID-19 multisystem inflammatory syndrome in children (MIS-C). All moderate and severe patients were hospitalized and received treatment (39%). Clear distinctions were seen between asymptomatic-mild cases and moderate-severe cases at acute timepoints and during disease progression for GCSF, IL-8, IL-10, IL-15, IL-1Ra, IP-10, MIP-1a, MIP-1β, and TGFα. There was a significant difference between participants who did and did not require hospitalization for acute timepoint levels of IL-10, IL-15, MIP-1 β and TGFα (p< 0.01). Only 4 participants with active COVID-19 were found to meet criteria for CSS (2%), only 3 of which were severe. MIS-C participants showed nearly universally elevated cytokine levels compared to those with active COVID-19. Temporal and severity associations of IL-10 and IP-10 [Image: see text] Figure 1. Temporal and severity associations of IL-10 and IP-10 Examples of differentiating cytokine profiles by severity and time. Among SARS-CoV-2 PCR positive participants, IL-10 and IP-10 displayed increased levels in their acute plasma samples as clinical severity increased [A,C]. IL-10 and IP-10 also showed distinct time-dependent responses (ln(Cytokine level (pg/mL)) that differentiated the more severe from the less severe groups [B,D]. CONCLUSION: Moderate and severe acute COVID-19 has a distinct cytokine profile from asymptomatic and mild cases, as detected from acute, subacute and convalescent plasma. DISCLOSURES: Joshua Wolf, MBBS, PhD, FRACP, Karius Inc. (Research Grant or Support) Joshua Wolf, MBBS, PhD, FRACP, Nothing to disclose Paul Thomas, PhD, Cytoagents (Consultant)Immunoscape (Consultant) Oxford University Press 2021-12-04 /pmc/articles/PMC8644557/ http://dx.doi.org/10.1093/ofid/ofab466.636 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Abstracts Green, Amanda M Souquette, Aisha Agrawal, Mona Wolf, Joshua Wolf, Joshua Gaur, Aditya Allison, Kim J Estepp, Jeremie Allen, Emma Thomas, Paul Smallwood, Heather 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups |
title | 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups |
title_full | 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups |
title_fullStr | 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups |
title_full_unstemmed | 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups |
title_short | 437. Longitudinal Plasma Cytokine Profiles Differentiating COVID-19 Severity Groups |
title_sort | 437. longitudinal plasma cytokine profiles differentiating covid-19 severity groups |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644557/ http://dx.doi.org/10.1093/ofid/ofab466.636 |
work_keys_str_mv | AT greenamandam 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT souquetteaisha 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT agrawalmona 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT wolfjoshua 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT wolfjoshua 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT gauraditya 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT allisonkimj 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT esteppjeremie 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT allenemma 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT thomaspaul 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups AT smallwoodheather 437longitudinalplasmacytokineprofilesdifferentiatingcovid19severitygroups |